Active, Not Recruiting
An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread. - CA009-002
Atualizado: | ClinicalTrials.gov
Fase
Gênero(s)
Faixa etária
Active, Not Recruiting
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - For Dose Escalation: - Subjects with any previously treated advanced (metastatic or refractory) solid tumor - For Cohort Expansion: - Subjects must have a previously treated advanced solid tumor to be eligible - Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 - Willing and able to provide pre-treatment and on-treatment fresh tumor biopsy - Women of child-bearing potential and men must use an acceptable method of contraception during treatment and for 23 weeks after treatment for women and 31 weeks for men Exclusion Criteria: - Known central nervous system metastases or central nervous system as the only source of disease - Other concomitant malignancies (with some exceptions per protocol) - Active, known or suspected autoimmune disease - Uncontrolled or significant cardiovascular disease - History of active or chronic hepatitis (e.g. Hep B or C) - Impaired liver or bone marrow function - Major surgery less than 1 month before start of the study
É altamente recomendável que você entre em contato com a BMS para relatar efeitos colaterais (eventos adversos).
Efeitos colaterais (eventos adversos) e outros eventos relatáveis estão definidos aqui.
Relate efeitos colaterais (eventos adversos) ou reclamações sobre a qualidade do produto: Informações médicas
